专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

31. 发明申请

US20070167241A1 Electromuscular incapacitation device and methods 有权
标题翻译：肌电无力的装置及方法
公开(公告)号：US20070167241A1
公开(公告)日：2007-07-19
申请号：US11509086
申请日：2006-08-23
申请人： Kenneth Stethem , Casey Hathcock , Bruno Marino , Anita Mehta , Robert Bernard , James Lee , Viet Pho
发明人： Kenneth Stethem , Casey Hathcock , Bruno Marino , Anita Mehta , Robert Bernard , James Lee , Viet Pho
IPC分类号： A63B15/00
CPC分类号： A01K15/02 , A22B3/06 , F41B15/04 , F41H9/10 , F41H13/0018 , F41H13/0025 , F41H13/0087
摘要： Incapacitation of a mammalian subject results from the application of a pulsed, low-power electric waveform. The waveform is applied to the subject at a frequency and over a time period sufficient to induce involuntary muscular contraction. Additionally, the contraction causes limited lactic acid production and is non- or minimally-injurious to the subject's tissues. A device utilizing such a waveform is designed to control or otherwise subdue an individual.
摘要翻译：哺乳动物受试者的失能是由应用脉冲，低功率电波形引起的。该波形以足以引起不自主肌肉收缩的频率和时间周期施加于受试者。此外，收缩导致有限的乳酸产生并且对受试者的组织是非或最小的损伤。使用这种波形的装置被设计成控制或以其他方式使个人屈服。

32. 发明申请

US20070135508A1 3,6-Disubstituted azabicyclo hexane derivatives as muscarinic receptor antagonists 失效
标题翻译： 3,6-二取代的氮杂双环己烷衍生物作为毒蕈碱受体拮抗剂
公开(公告)号：US20070135508A1
公开(公告)日：2007-06-14
申请号：US10552502
申请日：2003-04-10
申请人： Anita Mehta , Bruhaspathy Miriyala , Arundutt Silamkoti , Jang Gupta
发明人： Anita Mehta , Bruhaspathy Miriyala , Arundutt Silamkoti , Jang Gupta
IPC分类号： A61K31/403 , C07D405/02
CPC分类号： C07D209/52
摘要： The present invention relates to a radio telephony network (1) supporting at least one link of a radio channel (6) for a packet data transmission service. The radio telephony network (1) comprises a plurality of network controllers (RNC). Each network controller (RNC) is connected, via an interface Iub, to at least one base radio station (B-node) supervising at least one macrocell (5a). The radio telephony network (1) additionally comprises at least one base radio microstation (B1-micronode) connected to the network controller (RNC) via an interface Iub of the same type as that connecting the base radio station (B-node) to said controller. The base radio microstation (B1 micronode) supervises at least one microcell (5b) incorporated in at least one macrocell (5a). The base radio microstation (B1-micronode) provides the packet data transmission service in the microcell (5b) on the link of the radio channel (6).
摘要翻译：本发明涉及支持用于分组数据传输服务的无线电信道（6）的至少一个链路的无线电电话网络（1）。无线电电话网络（1）包括多个网络控制器（RNC）。每个网络控制器（RNC）经由接口Iub连接到监督至少一个宏小区（5a）的至少一个基站无线电台（B节点）。无线电电话网络（1）还包括经由与将基站无线电台（B节点）连接到所述网络控制器（RNC）的相同类型的接口Iub连接到网络控制器（RNC）的至少一个基站无线电微站（B1微米）控制器。基站无线电微型站（B1微处理器）监督并入至少一个宏小区（5a）中的至少一个微小区（5b）。基站无线电微站（B1-micronode）在无线电信道（6）的链路上的微小区（5b）中提供分组数据传输服务。

33. 发明申请

US20060293307A1 Oxazolidinone derivatives as antimicrobials 审中-公开
标题翻译：恶唑烷酮衍生物作为抗微生物剂
公开(公告)号：US20060293307A1
公开(公告)日：2006-12-28
申请号：US10523207
申请日：2002-07-29
申请人： Anita Mehta , Sonali Rudra , Ajjarapu Venkata Raja Rao , Ashok Rattan , Ajay Yadav
发明人： Anita Mehta , Sonali Rudra , Ajjarapu Venkata Raja Rao , Ashok Rattan , Ajay Yadav
IPC分类号： A61K31/551 , A61K31/496 , A61K31/498 , A61K31/454 , A61K31/473 , C07D413/14
CPC分类号： C07D413/12 , C07D413/14
摘要： The present invention relates to certain substituted phenyl oxazolidinones and to processes for the synthesis of the same. This invention also relates to pharmaceutical compositions containing the compounds of the present invention as antimicrobials. The compounds are useful antimicrobial agents, effective against a number of human and veterinary pathogens, including gram-positive aerobic bacteria such as multiple-resistant staphylococci, streptococci and enterococci as well as anaerobic organisms such as Bacterioides spp. and Clostridia spp. species, and acid fast organisms such as Mycobacterium tuberculosis, Mycobacterium avium and Mycobacterium spp.
摘要翻译：本发明涉及某些取代的苯基恶唑烷酮及其合成方法。本发明还涉及含有作为抗微生物剂的本发明化合物的药物组合物。这些化合物是有用的抗微生物剂，对许多人和兽医病原体有效，包括革兰氏阳性好氧细菌如多重耐药性葡萄球菌，链球菌和肠球菌以及厌氧生物如细菌属。和梭菌属（Clostridia spp。）物种和酸性快速生物如结核分枝杆菌，鸟分枝杆菌和分枝杆菌属。

34. 发明申请

US20060281805A1 Substituted azabicyclo hexane derivatives as muscarinic receptor antagonists 失效
公开(公告)号：US20060281805A1
公开(公告)日：2006-12-14
申请号：US10552456
申请日：2003-04-09
申请人： Anita Mehta , Bruhaspathy Miriyala , Sudershan Arora , Jang Gupta
发明人： Anita Mehta , Bruhaspathy Miriyala , Sudershan Arora , Jang Gupta
IPC分类号： A61K31/403 , C07D209/02
CPC分类号： C07D209/52
摘要： This invention relates to the derivatives of substituted azabicyclo hexanes. The compounds of this invention can function as muscarinic receptor antagonists and can be used for the treatment of various diseases of the respiratory, urinary and gastrointestinal systems mediated through muscarinic receptors. The invention also relates to a process for the preparation of the compounds of the present invention, pharmaceutical compositions containing the compounds of the present invention and the methods of treating the diseases mediated through muscarinic receptors.

35. 发明申请

US20060217432A1 3,6-Disubstituted azabicyclo [3.1.0] hexane derivatives as muscarinic receptor antagonists 失效
标题翻译： 3,6-二取代的氮杂双环[3.1.0]己烷衍生物作为毒蕈碱受体拮抗剂
公开(公告)号：US20060217432A1
公开(公告)日：2006-09-28
申请号：US10537851
申请日：2002-12-10
申请人： Anita Mehta , Arundutt Silamkoti , Bruhaspathy Miriyala , Sudershan Arora , Boju Srinivasulu , Bireshwar Mukherjee , Jang Gupta
发明人： Anita Mehta , Arundutt Silamkoti , Bruhaspathy Miriyala , Sudershan Arora , Boju Srinivasulu , Bireshwar Mukherjee , Jang Gupta
IPC分类号： A61K31/403 , C07D209/02
CPC分类号： C07D401/06 , C07D209/52 , C07D405/06 , C07D405/12 , C07D405/14 , C07D409/14
摘要： The invention relates to derivatives of 3,6-disubstituted azabicyclo[3.1.0]hexanes of structure (I). The compounds of this invention can function as muscarinic receptor antagonists, and can be used for the treatment of various diseases of the respiratory, urinary and gastrointestinal systems mediated through muscarinic receptors. The invention also relates to pharmaceutical compositions containing the compounds of the present invention and the methods for treating the diseases mediated through muscarinic receptors.
摘要翻译：本发明涉及结构（I）的3,6-二取代的氮杂双环[3.1.0]己烷的衍生物。本发明化合物可用作毒蕈碱受体拮抗剂，可用于治疗通过毒蕈碱受体介导的呼吸道，尿路和胃肠道系统的各种疾病。本发明还涉及含有本发明化合物的药物组合物和通过毒蕈碱受体介导的疾病的治疗方法。

36. 发明申请

US20060194862A1 1-Substituted-3-pyrrolidine derivatives as muscarinic receptor antagonists 失效
标题翻译： 1-取代的3-吡咯烷衍生物作为毒蕈碱受体拮抗剂
公开(公告)号：US20060194862A1
公开(公告)日：2006-08-31
申请号：US10540245
申请日：2002-12-23
申请人： Anita Mehta , Jang Gupta , Pakala Sarma
发明人： Anita Mehta , Jang Gupta , Pakala Sarma
IPC分类号： A61K31/4025 , A61K31/40 , C07D405/02 , C07D207/04
CPC分类号： C07D405/12 , C07D207/12 , C07D207/14
摘要： This invention generally relates to the derivatives of 1-substituted-3-pyrroli dines having the structure of Formula (I): The compounds of this invention can function as muscarinic receptor antagonists, and can be used for the treatment of various diseases of the respiratory, urinary and gastrointestinal systems mediated through muscarinic receptors. The invention also relates to a process for the preparation of the compounds of the present invention. pharmaceutical compositions containing the compounds of the present invention and the methods for treating the diseases mediated through muscarinic receptors.
摘要翻译：本发明一般涉及具有式（I）结构的1-取代-3-吡咯烷二醇衍生物：本发明化合物可用作毒蕈碱受体拮抗剂，可用于治疗各种呼吸疾病，通过毒蕈碱受体介导的尿路和胃肠道系统。本发明还涉及制备本发明化合物的方法。含有本发明化合物的药物组合物和通过毒蕈碱受体介导的疾病的治疗方法。

37. 发明申请

US20060142371A1 3,6-Disubstituted azabicyclo [3.1.0] hexane derivatives useful as muscarinic receptor 失效
标题翻译：用作毒蕈碱受体的3,6-二取代的氮杂双环[3.1.0]己烷衍生物
公开(公告)号：US20060142371A1
公开(公告)日：2006-06-29
申请号：US10524081
申请日：2002-08-09
申请人： Anita Mehta , Arundutt Silamkoti , Miriyala Bruhaspathy , Jang Gupta
发明人： Anita Mehta , Arundutt Silamkoti , Miriyala Bruhaspathy , Jang Gupta
IPC分类号： A61K31/403 , C07D209/02
CPC分类号： C07D209/02 , C07D209/52
摘要： This invention generally relates to the derivatives of 3,6 disubstituted azabicyclo[3.1.0]hexanes. The compounds of this invention are muscarinic receptor antagonists which are useful, inter-alia, for the treatment of various diseases of the respiratory, urinary and gastrointestinal systems mediated through muscarinic receptors. The invention also relates to a process for the preparation of the compounds of the present invention, pharmaceutical compositions containing the compounds of the present invention and the methods for treating the diseases mediated through muscarinic receptors.
摘要翻译：本发明一般涉及3,6-二取代的氮杂双环[3.1.0]己烷的衍生物。本发明的化合物是毒蕈碱受体拮抗剂，其特别用于治疗通过毒蕈碱受体介导的呼吸，尿和胃肠道系统的各种疾病。本发明还涉及制备本发明化合物的方法，含有本发明化合物的药物组合物和通过毒蕈碱受体介导的疾病的治疗方法。

38. 发明申请

US20060128781A1 Flavaxate derivatives as muscarinic receptor antagonists 失效
标题翻译：泛黄酸衍生物作为毒蕈碱受体拮抗剂
公开(公告)号：US20060128781A1
公开(公告)日：2006-06-15
申请号：US10540062
申请日：2002-12-23
申请人： Anita Mehta , Sanjay Srivastava , Jang Gupta
发明人： Anita Mehta , Sanjay Srivastava , Jang Gupta
IPC分类号： A61K31/403 , C07D405/02
CPC分类号： C07D209/52 , A61K31/352 , C07D405/12
摘要： This invention generally relates the derivatives of 3.6-disubstituted azabicyclo[3.1.0]hexanes of the following formula [IA]. The compounds of this invention can function as muscarinic receptor antagonists, and can be used for the treatment of various diseases of the respiratory, urinary and gastrointestinal systems mediated through muscarinic receptors. The invention also relates to a process for the preparation of the compounds of the present invention, pharmaceutical compositions containing the compounds of the present invention and the :h1ethods for treating the diseases mediated through muscarinic receptors.
摘要翻译：本发明通常涉及下式[IA]的3.6-二取代的氮杂双环[3.1.0]己烷的衍生物。本发明化合物可用作毒蕈碱受体拮抗剂，可用于治疗通过毒蕈碱受体介导的呼吸道，尿路和胃肠道系统的各种疾病。本发明还涉及制备本发明化合物的方法，含有本发明化合物的药物组合物和：用于治疗通过毒蕈碱受体介导的疾病的方法。

39. 发明申请

US20050209248A1 Plymorphic forms of phenyl oxazolidinone derivatives 审中-公开
标题翻译：苯基恶唑烷酮衍生物的多晶型
公开(公告)号：US20050209248A1
公开(公告)日：2005-09-22
申请号：US10514074
申请日：2003-05-15
申请人： Biswajit Das , Anita Mehta , Ashok Rattan
发明人： Biswajit Das , Anita Mehta , Ashok Rattan
IPC分类号： A61K31/496 , A61P31/00 , A61P31/04 , C07D413/12 , C07D413/14
CPC分类号： C07D413/12
摘要： The invention relates to phenyl oxazolidinone derivatives. More particularly, it relates to polymorphic forms of (S)-N-[[3-fluoro-4-[N-1[4-{2-furyl-(5-nitro)methyl}]piperazinyl]-phenyl]-2-oxo-5-oxazolidinyl]-methyl]acetamide hydrochloride having the Formula I. Further, the invention relates to methods of using such compounds as antimicrobials, pharmaceutical compositions containing the novel polymorphic forms, and processes for the preparation of the polymorphic forms.
摘要翻译：本发明涉及苯基恶唑烷酮衍生物。更具体地说，它涉及（S）-N - [[3-氟-4- [N-1 [4- {2-呋喃基 - （5-硝基）甲基}]哌嗪基] - 苯基] -2 - 氧代-5-恶唑烷基]甲基]乙酰胺盐酸盐。此外，本发明涉及使用这些化合物作为抗微生物剂的方法，含有新型多晶型物的药物组合物，以及制备多晶型物的方法。

40. 发明授权

US06821778B1 Methods for using dendritic cells to activate gamma/delta-T cell receptor-positive T cells 失效
标题翻译：使用树突状细胞激活γ/δ-T细胞受体阳性T细胞的方法
公开(公告)号：US06821778B1
公开(公告)日：2004-11-23
申请号：US08610195
申请日：1996-02-28
申请人： Edgar G. Engleman , Anita Mehta , Masaru Takamizawa , Francesco Fagnoni , Sergiusz Markowicz
发明人： Edgar G. Engleman , Anita Mehta , Masaru Takamizawa , Francesco Fagnoni , Sergiusz Markowicz
IPC分类号： C12N508
CPC分类号： C12N5/0636 , A61K2039/5158 , A61K2039/57
摘要： This invention relates to methods of using human dendritic cells to present antigens for the induction of antigen-specific T cell-mediated immune responses. In particular, it relates to the isolation of dendritic cells from human blood, exposing the cells to antigens, co-culturing the antigen-pulsed dendritic cells with &ggr;&dgr;-T cell receptor-positive-T cells (&ggr;&dgr;-TCR+ T cells) obtained from unprimed or weakly primed individuals for the stimulation of antigen-specific T cell proliferative and cytotoxic activities. The dendritic cell antigen presentation system described herein has a wide range of applications, including but not limited to, activation and expansion of large numbers of antigen-specific major histocompatibility complex-unrestricted T cells for use in adoptive cellular immunotherapy against infectious diseases and cancer.
摘要翻译：本发明涉及使用人树突状细胞呈递抗原以诱导抗原特异性T细胞介导的免疫应答的方法。特别地，它涉及从人血液中分离树突状细胞，将细胞暴露于抗原，用gammadelta-T细胞受体阳性T细胞（gammadelta-TCR + T细胞）共同培养抗原脉冲的树突状细胞）从未引导或弱引发的个体获得，用于刺激抗原特异性T细胞增殖和细胞毒活性。本文描述的树突状细胞抗原呈递系统具有广泛的应用，包括但不限于大量抗原特异性主要组织相容性复合物无限制T细胞的活化和扩增，用于针对传染病和癌症的过继细胞免疫治疗。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式